Velzatinib

Velzatinib (GSK6042981) is an investigational agent whose form is not stated in the registry developed by GlaxoSmithKline. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07585266 (A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (StrateGIST Frontline)), in gastrointestinal stromal tumour. The largest, NCT07585266, plans to enrol 800 participants with primary completion expected 2032-08-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.